(Health Korea News / Lee Soon-ho) On the 1st, Samjin Pharmaceutical launched ‘Samjindron Tablet (ingredient name: dronedarone hydrochloride)’, an oral antiarrhythmic drug prescribed for the treatment of atrial fibrillation.
‘Samjindrone tablet’ is the first generic version of the ingredient ‘dronedarone’. It is planned to spur growth in the antiarrhythmic drug market based on its economical drug price, which is 15% lower than the original (Sanofi’s ‘Multac tablet’).
Atrial fibrillation is a type of arrhythmia that forms an irregular pulse. It is a representative geriatric disease that can occur as the heart ages. According to medical statistics, the number of patients in Korea is continuously increasing to approximately 280,000 as of 2023. It has been confirmed that 1 in 10 elderly patients over the age of 80 have a risk of atrial fibrillation.
The indication for ‘Samjindronjeong’ is to reduce the risk of hospitalization due to atrial fibrillation in patients with normal sinus rhythm and a history of paroxysmal or persistent atrial fibrillation. In cases of atrial fibrillation, taking ‘Samjindronjeong’ can help control the heart rhythm and reduce the risk of arrhythmia recurrence.
The dronedarone component is recommended as a first-line drug for long-term rhythm control therapy regardless of the presence or absence of underlying heart disease in the 2020 European Society of Cardiology (ESC) guidelines. As of 2023, it has formed a domestic market of approximately KRW 10.9 billion and is currently continuing to grow.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
